ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Richard H. Feins
David W. Johnstone
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Feins, R. H.
Right arrow Articles by O'Neil, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feins, R. H.
Right arrow Articles by O'Neil, S. M.

Ann Thorac Surg 1996;62:1603-1607
© 1996 The Society of Thoracic Surgeons

Original Articles: General Thoracic

Palliation of Inoperable Esophageal Carcinoma With the Wallstent Endoprosthesis

Richard H. Feins, MD, David W. Johnstone, MD, Eleftherios S. Baronos, MD, Scott M. O'Neil, MD

University of Rochester Medical Center and Park Ridge Hospital, Rochester, New York

Accepted for publication June 24, 1996.

Background. Palliation of malignant dysphagia can be achieved by insertion of an endoprosthesis. Recently, metallic self-expanding prostheses have been introduced that offer the advantage of a lower complication rate over their plastic counterpart.

Methods. Thirteen patients with dysphagia due to inoperable carcinoma of the esophagus were treated with coated Wallstent (Schneider (USA) Inc, Minneapolis, MN) endoprostheses, which were placed under fluoroscopic control. All patients were given general anesthesia during the procedure.

Results. After successful insertion of all endoprosthe-ses, the dysphagia of 12 of the patients improved while in the hospital. Average length of stay was 4.4 days. Two patients required a second stent because of migration or tumor overgrowth. Seven patients died with a mean survival of 54 days (range, 14 to 144 days), and 6 are alive a mean of 112 days (range, 32 to 263 days) after treatment.

Conclusions. Coated Wallstent insertion is an effective, single treatment that quickly improves the patients' quality of life. Its effect on survival is yet to be established when used as a last resort in patients with inoperable esophageal carcinoma and poor general condition.




This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
C. J. Brinster, S. Singhal, L. Lee, M. B. Marshall, L. R. Kaiser, and J. C. Kucharczuk
Evolving options in the management of esophageal perforation
Ann. Thorac. Surg., April 1, 2004; 77(4): 1475 - 1483.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
A. Sarper, N. Oz, C. Cihangir, A. Demircan, and E. Isin
The efficacy of self-expanding metal stents for palliation of malignant esophageal strictures and fistulas
Eur. J. Cardiothorac. Surg., May 1, 2003; 23(5): 794 - 798.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
H. S. Park, Y. S. Do, S. W. Suh, S. W. Choo, H. K. Lim, S. H. Kim, Y. M. Shim, K. C. Park, and I. W. Choo
Upper Gastrointestinal Tract Malignant Obstruction: Initial Results of Palliation with a Flexible Covered Stent
Radiology, March 1, 1999; 210(3): 865 - 870.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1996 by The Society of Thoracic Surgeons.